

Lanreotide

A cyclic octapeptide somatostatin analog developed by Beaufour-Ipsen as the second clinically available long-acting somatostatin receptor ligand, distinguished by a unique self-assembling supersaturated depot formulation, antiproliferative activity in gastroenteropancreatic neuroendocrine tumors demonstrated in the landmark CLARINET trial, and a three-indication regulatory portfolio spanning acromegaly, neuroendocrine tumor growth control, and carcinoid syndrome.

DOCUMENT	KDC-MN-1391
ISSUED	2026-05-10
REVISION	1.0
AUTHOR	Kodi ac bio l ab s Research
COMPOUND CLASS	Synthetic cyclic octapeptide somatostatin analog with preferential somatostatin receptor subtype 2 and 5 agonism

ABSTRACT

Lanreotide (D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂; CAS 108736-35-2 free base; molecular formula C₅₄H₆₉N₁₁O₁₀S₂; molecular weight 1096.33) is a synthetic cyclic octapeptide analog of native somatostatin-14, developed by Beaufour-Ipsen (now Ipsen) and introduced clinically in the early 1990s as the second somatostatin analog to reach the market after octreotide. The compound exhibits high-affinity agonism at somatostatin receptor subtypes 2 and 5 (SSTR₂, K_i approximately 0.54 to 0.75 nM; SSTR₅, K_i approximately 5.2 nM) with moderate affinity at SSTR₃ and low affinity at SSTR₁ and SSTR₄, a selectivity profile that mediates suppression of growth hormone, insulin-like growth factor 1, and multiple gastrointestinal and pancreatic hormones through inhibition of adenylyl cyclase and reduction of intracellular cyclic adenosine monophosphate [1, 2]. The compound is formulated as lanreotide acetate in the Autogel (marketed as Somatuline Depot in the United States), a supersaturated aqueous gel in which lanreotide molecules self-assemble into hollow nanotubes of highly uniform diameter stabilized by beta-sheet hydrogen bonding, hydrophobic packing, and aromatic pi-pi stacking, producing a deep subcutaneous depot that releases active peptide over 28 days with a terminal elimination half-life of 23 to 30 days and absolute bioavailability of approximately 60 to 70 percent [3, 4]. The Autogel formulation, first approved in Europe in 2001 and in the United States in 2007, was the first marketed sustained-release pharmaceutical product produced by peptide self-assembly rather than by polymer microsphere encapsulation. Three indications are registered in the United States: long-term treatment of acromegaly in patients who

have had an inadequate response to or cannot be treated with surgery and radiotherapy (FDA approved August 2007); treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival (FDA approved December 2014, on the basis of the CLARINET trial); and treatment of carcinoid syndrome in adults to reduce the frequency of rescue somatostatin analog therapy (FDA approved February 2018, on the basis of the ELECT trial) [5, 6, 7]. In acromegaly, lanreotide Autogel at 60 to 120 mg every 28 days normalizes growth hormone to below 2.5 micrograms per liter in approximately 58 percent and age-adjusted insulin-like growth factor 1 in approximately 48 percent of treatment-naïve patients, with tumor volume reduction in approximately 60 percent of evaluated patients on long-term treatment [8, 9]. In the CLARINET trial, lanreotide 120 mg every 28 days versus placebo produced a hazard ratio for progression or death of 0.47 (95 percent confidence interval 0.30 to 0.73; P less than 0.001) in 204 patients with nonfunctioning, somatostatin-receptor-positive, grade 1 or 2 enteropancreatic neuroendocrine tumors, with estimated 24-month progression-free survival of 65.1 percent versus 33.0 percent [6]. In the ELECT trial, lanreotide 120 mg every 28 days significantly reduced the need for rescue short-acting octreotide for symptomatic carcinoid syndrome control and reduced patient-reported days with moderate or severe diarrhea and flushing [7]. The principal adverse events at registered doses are gastrointestinal (diarrhea 26 to 65 percent, abdominal pain 7 to 34 percent, nausea 5 to 11 percent), cholelithiasis and gallbladder sludge (14 to 20 percent), injection site reactions (5 to 22 percent), dysglycemia (hyperglycemia 5 to 14 percent, hypoglycemia 2 to 7 percent), and sinus bradycardia (3 to 8 percent) [10]. This

monograph reviews the chemistry, synthesis, and self-assembly of lanreotide; the somatostatin receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record; the preclinical antiproliferative pharmacology; the clinical evidence base across acromegaly, neuroendocrine tumor, and carcinoid syndrome indications; reconstitution and handling; sourcing and quality verification; stack-interaction considerations; adverse-event signal; and a comparative assessment of five somatostatin receptor ligands against lanreotide on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Lanreotide.

Marketed names: Somatuline Depot (Ipsen; United States), Somatuline Autogel (Ipsen; European Union, United Kingdom, Australia, Canada, Japan, and other markets), Somatuline LA (Ipsen; earlier microsphere formulation, largely superseded), Ipstyl (Italy and other Southern European markets).

Development codes: BIM-23014 (Beaufour-Ipsen). The development code is the canonical identifier in the early pharmacology literature and in receptor binding studies predating the international nonproprietary name assignment [1].

Chemical Abstracts Service registry numbers: 108736-35-2 (free base), 127984-74-1 (acetate salt). The acetate salt is the formulated pharmaceutical form in all marketed preparations; the free base is the synthetic and analytical reference form.

Amino acid sequence: D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂, with a disulfide bridge between the two cysteine residues at positions 2 and 7 forming the cyclic structure. The C-terminal threonine bears a primary amide [1, 11].

International Union of Pure and Applied Chemistry name: (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide.

1.2 Structural class and chemistry

Lanreotide is a cyclic octapeptide analog of somatostatin-14 (somatotropin release-inhibiting factor, SRIF-14). Native somatostatin-14 is a 14-amino-acid cyclic peptide (Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys, cyclized through a Cys³-Cys¹⁴ disulfide) with a plasma half-life of approximately 2 to 3 minutes, far too short for therapeutic use. Lanreotide retains the pharmacophoric tetrapeptide core (Phe-Trp-Lys-Thr in native somatostatin, replaced by Tyr-D-Trp-Lys-Val in lanreotide) responsible for receptor binding, incorporates the D-tryptophan and D-2-

naphthylalanine substitutions that confer resistance to enzymatic degradation, and reduces the ring size from 14 to 8 amino acids to produce a metabolically stable cyclic structure with a disulfide bridge between Cys2 and Cys7 [1, 2].

Molecular formula: C₅₄H₆₉N₁₁O₁₀S₂ (free base).

Molecular weight: 1096.33 g/mol (free base); 1156.39 g/mol (acetate salt, accounting for one acetate counterion).

Physical properties: White to off-white lyophilized powder (free base and acetate). The acetate salt is soluble in water and in acetic acid solutions; solubility increases markedly in aqueous acetic acid at concentrations above 5 percent, which is the basis for the supersaturated Autogel formulation. Sparingly soluble in most organic solvents. The compound is hygroscopic in the lyophilized state.

Stereochemistry: Lanreotide contains two non-proteinogenic D-amino acids (D-2-naphthylalanine at position 1 and D-tryptophan at position 4) and six L-amino acids with their natural stereochemistry. The disulfide bridge between Cys2 and Cys7 constrains the ring conformation and is essential for receptor binding affinity. Investigators acquiring research-grade lanreotide should confirm disulfide integrity by mass spectrometry and reversed-phase high-performance liquid chromatography, as the reduced (linear) form has substantially diminished receptor affinity.

1.3 Synthesis

The synthesis of lanreotide proceeds by solid-phase peptide synthesis using standard Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert-butyloxycarbonyl) chemistry on a resin support [11, 12]. The linear octapeptide precursor (D-2Nal-Cys(Trt)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Val-Cys(Trt)-Thr(tBu)-resin) is assembled by sequential coupling of protected amino acids using standard activating reagents (HBTU, HATU, or DIC/HOBt). After complete chain assembly, the peptide is cleaved from the resin with simultaneous side-chain deprotection using trifluoroacetic acid with appropriate scavengers. The crude linear peptide is purified by preparative reversed-phase high-performance liquid chromatography and subsequently cyclized by air oxidation or iodine-mediated oxidative disulfide formation in dilute aqueous solution at pH 7 to 8. The cyclic product is purified a second time by preparative reversed-phase HPLC, characterized by electrospray ionization mass spectrometry and analytical HPLC, and lyophilized. Conversion to the acetate salt is accom-

plished by dissolution in dilute acetic acid followed by lyophilization. Industrial-scale synthesis achieves the cyclic product in overall yields of approximately 25 to 40 percent from the resin-bound linear precursor, with purity greater than 98 percent by analytical HPLC [12].

The Autogel formulation is prepared by dissolving lanreotide acetate in water at a concentration of approximately 24.6 percent weight per volume (corresponding to 60, 90, or 120 mg per prefilled syringe) with acetic acid at a controlled concentration (approximately 5.7 to 11.0 percent). At these concentrations, lanreotide spontaneously self-assembles into nanotubes of approximately 24 nanometers external diameter and approximately 10 nanometers internal diameter, stabilized by noncovalent interactions between antiparallel beta-sheet dimeric subunits. The resulting formulation is a semi-solid, white, supersaturated gel that can be administered by deep subcutaneous injection through a standard needle [3, 4, 13].

2. Abstract

Lanreotide (BIM-23014) is a synthetic cyclic octapeptide somatostatin analog with high-affinity agonism at somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), developed by Beaufour-Ipsen and brought to market as the second long-acting somatostatin receptor ligand after octreotide [1, 2]. The compound inhibits growth hormone, insulin-like growth factor 1, thyroid-stimulating hormone, and multiple gastrointestinal and pancreatic hormones through G-protein-coupled receptor-mediated suppression of adenylyl cyclase, and exerts direct and indirect antiproliferative effects on neuroendocrine and other tumor cells through cell cycle arrest, apoptosis induction, angiogenesis inhibition, and immunomodulatory mechanisms [14, 15].

The clinical development of lanreotide has produced a three-indication regulatory portfolio in the United States and broader approvals in Europe, Japan, and approximately 60 other jurisdictions. In acromegaly, the compound at 60 to 120 mg every 28 days by deep subcutaneous injection normalizes growth hormone to below 2.5 micrograms per liter in approximately 58 percent and age-adjusted insulin-like growth factor 1 in approximately 48 percent of somatostatin-receptor-ligand-naïve patients, with significant tumor shrinkage in approximately 60 percent of patients on long-term therapy [8, 9, 16]. In gastroenteropancreatic neuroendocrine tumors, the CLARINET trial (Caplin et al. 2014, New England Journal of Medicine) demonstrated that lanreotide 120 mg every 28 days versus placebo produced a 53 percent reduction in the risk of disease progression or death (hazard ratio 0.47, P less than 0.001) in 204 patients with nonfunctioning, well- or moderately-differentiated, grade 1 or 2 tumors, establishing the compound as the first somatostatin analog to receive an FDA indication for antiproliferative treatment of neuroendocrine tumors on the basis of a randomized controlled trial [6]. In carcinoid syndrome, the ELECT trial (Vinik et al. 2016) demonstrated significant reduction in the need for rescue somatostatin analog therapy and in patient-reported symptoms of diarrhea and flushing [7].

The Autogel formulation (Somatuline Depot in the United States) is the defining pharmaceutical innovation of lanreotide: a supersaturated aqueous gel in which lanreotide molecules spontaneously self-assemble into hollow nanotubes of highly uniform diameter, producing a subcutaneous depot with slow, sustained release

over 28 days without the polymer microsphere matrix used by octreotide LAR [3, 4, 13]. The formulation enables patient self-injection and has an elimination half-life of approximately 23 to 30 days, supporting the 28-day dosing interval.

The principal adverse events are gastrointestinal (diarrhea, abdominal pain, nausea, flatulence), cholelithiasis and gallbladder sludge, injection site reactions, dysglycemia (hyperglycemia and hypoglycemia reflecting suppression of both insulin and glucagon secretion), and sinus bradycardia [10]. The compound is not metabolized through cytochrome P450 enzymes; drug-drug interactions are mediated principally through pharmacodynamic effects on gastrointestinal motility (reduced cyclosporine absorption), growth hormone suppression (altered CYP-substrate clearance), and glucose homeostasis (altered insulin requirements) [17].

This monograph documents the chemistry, self-assembly, and formulation of lanreotide; somatostatin receptor pharmacology; pharmacokinetics; preclinical antiproliferative pharmacology; the clinical evidence base across acromegaly, neuroendocrine tumor, and carcinoid syndrome indications; reconstitution and handling; sourcing and quality verification; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five somatostatin receptor ligands (octreotide, pasireotide, somatoprim, ¹⁷⁷Lu-DOTATATE, and surufatinib) against lanreotide on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

3. Discovery and Development History

3.1 Origin

Lanreotide (BIM-23014) was developed in the 1980s by Beaufour-Ipsen (now Ipsen) in France as part of a medicinal chemistry program to produce metabolically stable somatostatin analogs with prolonged duration of action relative to the very short plasma half-life (2 to 3 minutes) of native somatostatin-14 [1, 2]. The compound design was informed by the earlier work of Veber, Bauer, and colleagues at Merck and by Bauer and Coy at Tulane that had identified the Phe-Trp-Lys-Thr tetrapeptide as the minimal pharmacophore for somatostatin receptor binding, and by the success of octreotide (SMS 201-995, Sandoz, now Novartis), which was the first somatostatin analog to achieve clinical registration in 1988 [18, 19]. Lanreotide was designed to improve on the native somatostatin framework through substitution of D-2-naphthylalanine (D-2Nal) at position 1 for enhanced metabolic stability and hydrophobic receptor interaction, incorporation of D-tryptophan at position 4 for protease resistance, and retention of the Cys-Cys disulfide cyclization that constrains the ring to the bioactive conformation.

3.2 Early formulations and regulatory history

The first marketed lanreotide formulation was Somatuline LA (lanreotide acetate in poly-DL-lactide-co-glycolide microspheres), an intramuscular long-acting release product requiring administration every 7 to 14 days, first approved in France in 1994 for acromegaly [20]. The microsphere formulation had limitations in injection consistency, reconstitution complexity, and dosing flexibility that motivated the development of the Autogel formulation.

The Autogel formulation (Somatuline Autogel in European markets, Somatuline Depot in the United States) was developed over approximately 8 years at Ipsen under the leadership of Joel Richard and colleagues. The key scientific insight was that lanreotide acetate at supersaturating concentrations in aqueous acetic acid solution spontaneously self-assembles into nanotubes, producing a semi-solid gel that could serve as its own sustained-release depot without a polymer matrix [3, 4]. The

Autogel received its first European approval in 2001 and was approved by the United States Food and Drug Administration on August 30, 2007 for the long-term treatment of acromegaly [5].

3.3 Expansion of indications

The acromegaly indication was the original regulatory basis for lanreotide in all jurisdictions. The compound was subsequently studied in neuroendocrine tumors on the basis of preclinical and clinical evidence of somatostatin analog antiproliferative activity. The CLARINET trial (Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors), published by Caplin et al. in 2014 in the New England Journal of Medicine, was the pivotal randomized controlled trial that demonstrated the antiproliferative efficacy of lanreotide in gastroenteropancreatic neuroendocrine tumors [6]. The FDA approved the neuroendocrine tumor indication on December 16, 2014.

The carcinoid syndrome indication was supported by the ELECT trial (Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment), published by Vinik et al. in 2016 [7]. The FDA approved the carcinoid syndrome indication on February 2, 2018.

The CLARINET open-label extension (CLARINET OLE), published by Caplin et al. in 2020, confirmed sustained antiproliferative benefit with extended lanreotide treatment beyond the original trial period, with median treatment duration exceeding 3 years [21].

3.4 Generic competition and current status

Patent protection for the lanreotide Autogel formulation has been the subject of extensive litigation. Generic lanreotide acetate injection products were approved by the FDA beginning in 2023. Ipsen has reported supply challenges related to the complexity of the self-assembling nanotube formulation. As of the most recent monograph revision, lanreotide remains available in branded (Somatuline Depot) and generic forms in the United States and in more than 60 jurisdictions worldwide. The compound is not a controlled substance in any jurisdiction.

4. Mechanism of Action

Lanreotide is a somatostatin receptor agonist. Its principal molecular activity is high-affinity agonism at the somatostatin receptor subtypes SSTR2 and SSTR5, with moderate affinity at SSTR3 and low affinity at SSTR1 and SSTR4. These five somatostatin receptor subtypes are G-protein-coupled receptors of the rhodopsin family that couple through inhibitory G-proteins (Gi/Go) to inhibit adenylyl cyclase, activate potassium channels, and inhibit voltage-dependent calcium channels [1, 2, 14].

4.1 Somatostatin receptor binding and selectivity

The binding affinity profile of lanreotide has been characterized in multiple radioligand displacement assays using membranes from cells transfected with individual human somatostatin receptor subtypes:

SSTR2: Ki approximately 0.54 to 0.75 nM (high affinity, comparable to octreotide)
SSTR5: Ki approximately 5.2 nM (high affinity, similar to octreotide) SSTR3: Ki approximately 14 to 107 nM (moderate affinity) SSTR1: Ki approximately 500 to 2330 nM (low affinity) SSTR4: Ki greater than 1000 nM (negligible affinity)

The selectivity profile places lanreotide in the same first-generation somatostatin analog class as octreotide, with preferential SSTR2 and SSTR5 binding. This is distinct from the second-generation analog pasireotide, which has higher affinity at SSTR5 and broader multireceptor binding [1, 22].

4.2 Hormonal suppression

The principal endocrine consequence of SSTR2 and SSTR5 agonism is suppression of hormone secretion from the anterior pituitary, the pancreatic islets, and the gastrointestinal neuroendocrine system:

Growth hormone: SSTR2 and SSTR5 are the predominant somatostatin receptor subtypes expressed on somatotroph cells of the anterior pituitary. Lanreotide binding activates inhibitory G-proteins, reduces intracellular cAMP, and suppresses both basal and stimulated growth hormone secretion. The downstream consequence is reduced hepatic insulin-like growth factor 1 (IGF-1) production [2, 8].

Thyroid-stimulating hormone: SSTR2 is expressed on thyrotroph cells. Lanreotide suppresses TSH secretion, which is the basis for the historical investigation of somatostatin analogs in TSH-secreting pituitary adenomas [14].

Insulin and glucagon: SSTR2 (on alpha cells) and SSTR5 (on beta cells) mediate suppression of both glucagon and insulin secretion from pancreatic islets. The net glycemic effect is variable; the suppression of insulin frequently predominates, producing hyperglycemia, particularly in patients with impaired glucose tolerance [10, 17].

Gastrointestinal hormones: Lanreotide suppresses the secretion of gastrin, cholecystokinin, secretin, vasoactive intestinal peptide, motilin, serotonin (5-HT), and other gastrointestinal peptides through SSTR2 agonism on enteroendocrine cells. The serotonin suppression is the principal mechanism for the carcinoid syndrome symptom control indication [7, 14].

4.3 Antiproliferative mechanisms

The antiproliferative activity of lanreotide is mediated through both direct and indirect mechanisms [14, 15, 23]:

Direct effects: SSTR2 and SSTR3 activation on tumor cells produces cell cycle arrest at G1-G0 through induction of the cyclin-dependent kinase inhibitor p27Kip1, activation of protein phosphatases (SHP-1, SHP-2), and modulation of the PI3K/Akt/mTOR signaling pathway. SSTR2 and SSTR3 activation can also induce apoptosis through caspase-dependent and mitochondrial pathways. These direct effects have been demonstrated in vitro in neuroendocrine tumor cell lines, pituitary adenoma primary cultures, and pancreatic cancer cell lines at concentrations of 0.1 to 25 micromolar [15, 23].

Indirect effects: Suppression of growth hormone and IGF-1 removes trophic stimulation of tumor growth. Inhibition of vascular endothelial growth factor (VEGF) secretion and reduction of tumor angiogenesis have been demonstrated in preclinical models. Immunomodulatory effects, including modulation of natural killer cell activity and cytokine release, contribute to the antitumor response [14, 15].

4.4 Effects on gastrointestinal motility and gallbladder

Lanreotide inhibits gallbladder contractility and bile secretion through SSTR2-mediated suppression of cholecystokinin signaling, reducing postprandial gallbladder emptying and promoting bile stasis. This mechanism is the basis for the high incidence of cholelithiasis and gallbladder sludge observed in clinical use [10]. Gastrointestinal motility is reduced through SSTR2 agonism on enteric neurons and smooth muscle, producing dose-dependent effects on gastric emptying, small bowel transit, and colonic motility that manifest clinically as alternating diarrhea and steatorrhea (from exocrine pancreatic insufficiency) or constipation depending on the balance of secretory and motility effects [14].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption and depot release

The Autogel formulation is administered by deep subcutaneous injection, typically into the upper outer quadrant of the buttock. After injection, the semi-solid nanotube gel forms a depot from which lanreotide is slowly released by nanotube disassembly. The release profile is characterized by an initial burst (peak serum concentration within approximately 0.5 to 1 day of injection), followed by sustained release over the next 28 days [3, 4].

Mean peak serum concentration (C_{max}) after a single subcutaneous injection of lanreotide Autogel 120 mg in healthy volunteers is approximately 5.7 to 8.3 nanograms per milliliter, with median time to C_{max} of 0.3 to 1 day [3]. Steady-state serum trough concentrations at the end of a 28-day dosing interval are approximately 1.8 to 3.2 nanograms per milliliter for the 120 mg dose in acromegalic patients [4].

Absolute bioavailability after deep subcutaneous administration of lanreotide Autogel is approximately 60 to 70 percent, with the incomplete bioavailability attributable to local degradation at the injection site [3, 4]. The rate of absorption and bioavailability are independent of dose in the range of 60 to 120 mg, and no significant effects of sex, age, or body weight on these parameters have been demonstrated in population pharmacokinetic analyses [24].

5.2 Distribution

Lanreotide has moderate plasma protein binding of approximately 78 to 83 percent, predominantly to lipoprotein and to a lesser extent albumin. The volume of distribution at steady state has not been precisely characterized from the depot formulation owing to the flip-flop kinetics (absorption-rate-limited elimination), but after intravenous administration of the earlier formulation, the volume of distribution is approximately 0.2 to 0.4 liters per kilogram, reflecting primarily extracellular distribution with limited tissue partitioning [4, 14].

5.3 Metabolism

Lanreotide is metabolized by peptide hydrolysis and by enzymatic degradation at multiple sites. The compound is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes [17]. The principal metabolic pathways involve cleavage of the disulfide bond, hydrolysis of the C-terminal amide, and progressive peptide bond cleavage. No single active metabolite has been identified; the metabolites have markedly reduced somatostatin receptor affinity relative to the parent compound [4, 14].

5.4 Elimination

The terminal elimination half-life of lanreotide from the Autogel formulation is approximately 23 to 30 days, reflecting absorption-rate-limited (flip-flop) kinetics in which the slow release from the subcutaneous depot determines the apparent elimination rate [3, 4, 24]. The intrinsic peptide elimination half-life (measured after intravenous administration) is approximately 1 to 2 hours.

Lanreotide is excreted primarily through the gastrointestinal tract (bile and intestinal secretion) with less than 5 percent of an administered dose recovered unchanged in urine. Renal impairment has moderate effects on lanreotide clearance; the FDA label recommends a starting dose of 60 mg in patients with moderate to severe renal impairment. Hepatic impairment similarly reduces clearance and warrants dose adjustment [4, 10].

5.5 Routes of administration

Deep subcutaneous injection (Autogel/Depot): The registered and standard route. Doses of 60, 90, and 120 mg are available in prefilled syringes for injection every 28 days into the deep subcutaneous tissue of the upper outer buttock. The formulation supports patient or caregiver self-injection after appropriate training [5].

Intramuscular injection (Somatuline LA): The earlier microsphere formulation was administered intramuscularly every 7 to 14 days. This formulation has been largely superseded by the Autogel [20].

Intravenous and subcutaneous bolus: Research-grade lanreotide acetate has been administered intravenously and subcutaneously in research settings; these routes are not registered and produce a short duration of action consistent with the

intrinsic peptide half-life of 1 to 2 hours.

5.6 Special populations

Elderly patients show no clinically significant differences in pharmacokinetics compared to younger adults at standard doses. Pediatric pharmacokinetics have not been extensively studied; lanreotide is not approved for pediatric use. Pregnancy category is not formally assigned by the FDA; animal reproductive toxicity studies have shown embryofetal effects at doses above clinical levels, and lanreotide is generally not recommended during pregnancy or lactation [10].

6. Preclinical Pharmacology

6.1 In vitro antiproliferative activity

Lanreotide has been characterized in vitro for antiproliferative activity across multiple cell lines. In human pituitary adenoma primary cultures, lanreotide at concentrations of 1 to 10 nanomolar inhibited growth hormone secretion and DNA synthesis, with the antisecretory effect substantially more potent than the antiproliferative effect at equimolar concentrations [15, 23]. In neuroendocrine tumor cell lines (BON-1, QGP-1, NCI-H727), lanreotide at 0.1 to 25 micromolar produced dose-dependent inhibition of proliferation, with IC50 values of approximately 25 micromolar in some systems [15]. The antiproliferative effect was maximal after 72 hours of exposure and was mediated through SSTR2, as demonstrated by reversal with SSTR2-selective antagonists and by absence of effect in SSTR2-negative cell lines.

Savelli et al. (2024) demonstrated that concomitant inhibition of PI3K/mTOR signaling pathways boosts the antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells, suggesting combination strategies for clinical development [25].

6.2 In vivo tumor models

In xenograft models of neuroendocrine tumors in nude mice, lanreotide at subcutaneous doses of 0.3 to 3 mg/kg/day produced dose-dependent inhibition of tumor growth, with tumor volume reductions of 40 to 70 percent relative to vehicle control over 28-day treatment periods [14, 15]. The antitumor effect was associated with reduced tumor microvessel density (consistent with angiogenesis inhibition) and with increased apoptotic index in tumor sections.

6.3 Angiogenesis inhibition

Preclinical studies have demonstrated that lanreotide inhibits vascular endothelial growth factor (VEGF) secretion from tumor cells and reduces endothelial cell proliferation in vitro at concentrations of 1 to 10 micromolar [14, 15]. The anti-angio-

genic effect is mediated through SSTR2 and contributes to the indirect antiproliferative mechanism.

6.4 Immunomodulatory effects

Lanreotide modulates cytokine release from immune cells, including suppression of tumor necrosis factor alpha and interleukin-6 from activated macrophages, and modulation of natural killer cell activity [14]. Vitale et al. (2020) demonstrated that lanreotide induces cytokine modulation in intestinal neuroendocrine tumors and overcomes resistance to the mTOR inhibitor everolimus, providing preclinical rationale for combination regimens [26].

7. Clinical Evidence Base

7.1 Acromegaly

Acromegaly is the original and most extensively studied indication for lanreotide. The disease results from chronic excess growth hormone secretion, almost always from a pituitary somatotroph adenoma, producing elevated IGF-1, somatic overgrowth, metabolic complications (diabetes, cardiovascular disease), and reduced life expectancy if untreated.

Efficacy of hormonal control: Pooled analyses of clinical trials in somatostatin-receptor-ligand-naïve patients receiving lanreotide Autogel at 60 to 120 mg every 28 days demonstrate GH normalization (GH less than 2.5 micrograms per liter) in approximately 58 percent and age-adjusted IGF-1 normalization in approximately 48 percent of patients, with the normalization rate dependent on baseline hormone levels, tumor size, and SSTR2 expression density [8, 9, 16]. The PRIMARYS study, a 48-week, single-arm, open-label study in 90 treatment-naïve acromegaly patients receiving lanreotide Autogel 120 mg, reported that 34.4 percent of patients achieved IGF-1 normalization by week 48, with significant tumor volume reduction of 20 percent or more in 63 percent of evaluable patients [27].

Tumor shrinkage: Long-term treatment with lanreotide Autogel produces clinically meaningful tumor volume reduction in approximately 60 percent of patients. Colao et al. (2001) reported GH/IGF-I normalization and tumor shrinkage during long-term treatment, with some patients achieving greater than 50 percent volume reduction over 2 to 5 years of continuous therapy [16].

Dose titration: The registered dose range is 60 to 120 mg every 28 days, with titration based on biochemical response (GH and IGF-1 levels) and clinical symptoms. High-dose and high-frequency regimens (120 mg every 21 days, or 180 mg every 28 days) have been studied in patients with inadequate response to standard doses, with incremental hormonal control in approximately 20 to 30 percent of prior partial responders [28].

Long-term outcomes: The compound has been administered continuously for more than 10 years in individual patients with sustained hormonal control and without evidence of tachyphylaxis.

7.2 Gastroenteropancreatic neuroendocrine tumors

The CLARINET trial (Caplin et al. 2014) is the landmark study establishing the antiproliferative efficacy of lanreotide in gastroenteropancreatic neuroendocrine tumors [6]. The trial was a randomized, double-blind, placebo-controlled, multinational study in 204 patients with nonfunctioning, somatostatin-receptor-positive, well- or moderately-differentiated (grade 1 or 2, Ki-67 less than 10 percent), locally advanced or metastatic enteropancreatic neuroendocrine tumors. Patients were randomized to lanreotide Autogel 120 mg or placebo every 28 days for up to 96 weeks.

Primary endpoint: Progression-free survival. Lanreotide was associated with significantly prolonged PFS compared to placebo: the median PFS was not reached in the lanreotide group versus 18.0 months in the placebo group (hazard ratio 0.47; 95 percent CI 0.30 to 0.73; P less than 0.001) [6].

24-month PFS rates: 65.1 percent (lanreotide) versus 33.0 percent (placebo).

Subgroup analyses: The treatment effect was consistent across prespecified subgroups defined by primary tumor site (pancreas versus midgut versus hindgut), hepatic tumor burden, and baseline progression status. The benefit was observed in both progressive and stable disease at baseline, although it was numerically greater in the progressive disease subgroup.

CLARINET open-label extension: Caplin et al. (2020) reported continued antiproliferative benefit with extended treatment, with median overall treatment duration exceeding 3 years. The safety profile in the extension was consistent with the double-blind phase [21].

The CLARINET results, together with the earlier PROMID trial of octreotide LAR in midgut neuroendocrine tumors (Rinke et al. 2009), established somatostatin analogs as standard first-line antiproliferative therapy for well-differentiated, somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors [29].

7.3 Carcinoid syndrome

The ELECT trial (Vinik et al. 2016) evaluated lanreotide Autogel 120 mg every 28 days versus placebo for symptomatic control of carcinoid syndrome (diarrhea and flushing caused by serotonin and other hormone secretion from neuroendocrine tumors) [7].

Study design: Randomized, double-blind, placebo-controlled, 16-week trial with a 32-week open-label extension. Patients with or without prior somatostatin analog use were enrolled. Rescue short-acting octreotide was available for symptom breakthrough.

Primary endpoint: Percentage of days requiring rescue octreotide. Lanreotide significantly reduced the need for rescue therapy compared to placebo.

Patient-reported outcomes: Lanreotide was associated with significant reductions in the percentage of days with moderate or severe diarrhea and flushing, and these improvements were sustained through the 32-week open-label extension for a total treatment duration of 48 weeks [7, 30].

7.4 Other investigated indications

Thyroid-stimulating hormone-secreting pituitary adenomas (thyrotropinomas): Case series and retrospective studies have reported biochemical and tumor control with lanreotide in TSH-secreting adenomas, consistent with SSTR2 expression on thyrotroph cells [14].

Polycystic liver and kidney disease: Randomized controlled trials have demonstrated that lanreotide reduces liver and kidney volume in autosomal dominant polycystic liver and kidney disease through suppression of cAMP-mediated cyst fluid secretion in cholangiocytes and renal tubular epithelial cells. The DIPAK-1 trial (Meijer et al. 2018) and the ALADIN trials have provided the principal evidence base [31].

Refractory diarrhea: Lanreotide has been used off-label for refractory secretory diarrhea of various etiologies, including short bowel syndrome, postgastrectomy dumping syndrome, and chemotherapy-induced diarrhea, on the basis of the anti-secretory mechanism [14].

8. Sourcing and Quality Verification

Pharmaceutical-grade lanreotide (Somatuline Depot brand or FDA-approved generic equivalents) is the highest-quality source for any research application where regulatory equivalence to clinical material is operationally important. The pharmaceutical-grade material is supplied as a prefilled syringe containing a supersaturated lanreotide acetate aqueous gel at concentrations corresponding to 60 mg, 90 mg, or 120 mg per injection, for deep subcutaneous administration.

Research-grade lanreotide acetate is supplied by multiple peptide and chemical research suppliers (Bachem, Tocris, Sigma-Aldrich, MedChemExpress, Selleckchem, Cayman Chemical, BOC Sciences, Santa Cruz Biotechnology, and others) at greater than 95 percent purity by HPLC, typically as a lyophilized powder of the acetate salt. Pricing varies from approximately \$100 to \$400 per milligram of research-grade material at the time of monograph preparation, reflecting the cost of solid-phase peptide synthesis with oxidative cyclization.

Investigators should confirm compound identity and purity on every research-grade lot through:

- Reversed-phase high-performance liquid chromatography area-percent purity, ideally greater than 95 percent, with greater than 98 percent preferred for dose-response and receptor binding studies
- Electrospray ionization mass spectrometry confirmation of molecular weight (expected $[M+H]^+$ of 1097.34 for the free base)
- Confirmation of disulfide bridge integrity by mass spectrometry under non-reducing conditions (the reduced, linear form will show a mass shift of +2 Da and has substantially diminished receptor affinity)
- Amino acid analysis to confirm composition consistent with the D-2Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr sequence
- Residual solvent analysis (trifluoroacetic acid, acetonitrile, and other common HPLC solvents from preparative purification)
- Endotoxin testing (Limulus amoebocyte lysate or recombinant Factor C assay) for any material intended for in vivo administration

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, others) provide independent verification of vendor certificates of analysis. The research-grade lanreotide market is smaller than the octreotide market; lot-to-lot variability in purity, counterion content, and residual TFA is observed, and on-receipt analytical confirmation is appropriate for any investigation where receptor pharmacology or dose-response precision is important.

9. Reconstitution and Handling

The pharmaceutical Autogel formulation is supplied as a ready-to-use prefilled syringe and requires no reconstitution. The syringe should be stored refrigerated at 2 to 8 degrees Celsius in the original packaging until use. The product may be stored at room temperature (up to 25 degrees Celsius) for up to 4 weeks before use in the unopened original packaging [5, 10].

For research applications, lanreotide acetate lyophilized powder is reconstituted in sterile water for injection, normal saline, or dimethyl sulfoxide (for in vitro applications where higher concentrations are required). Stock solutions in aqueous vehicles should be prepared at concentrations of 0.1 to 10 mg/mL and used within 24 hours if prepared in sterile water, or within 7 to 14 days if prepared in bacteriostatic water and stored at 2 to 8 degrees Celsius. DMSO stock solutions may be stored at minus 20 degrees Celsius for up to 6 months.

The following handling considerations apply:

- The compound is stable as a lyophilized powder at minus 20 degrees Celsius for at least 2 years when protected from moisture
- Aqueous solutions at neutral pH are susceptible to peptide hydrolysis; solutions should be prepared fresh or used within the stability window noted above
- At concentrations above approximately 20 mg/mL in aqueous acetic acid, the compound will self-assemble into the nanotube gel phase; this concentration is above the range used in most research applications but investigators should be aware of the self-assembly phenomenon
- Freeze-thaw cycles should be minimized; aliquoting of stock solutions for single use is recommended
- Light protection is not specifically required but is reasonable practice for peptide solutions
- The compound adsorbs to uncoated glass and some plastics at low concentrations; siliconized glassware or low-binding polypropylene tubes should be used for dilute solutions (below 1 microgram per milliliter)

10. Stack Interactions and Combinations

Lanreotide interacts with several drug classes through its pharmacodynamic effects on hormone secretion, gastrointestinal motility, and cardiac conduction. Investigators conducting research with lanreotide, especially in chronic dosing regimens, should consider:

Insulin and oral hypoglycemic agents: Lanreotide suppresses both insulin and glucagon secretion. The net glycemic effect is variable but hyperglycemia predominates, especially in patients with pre-existing impaired glucose tolerance or diabetes. Dose adjustments of insulin, sulfonylureas, and other hypoglycemic agents may be required. Blood glucose should be monitored when lanreotide is initiated, when the dose is changed, and during chronic therapy [10, 17].

Cyclosporine: Lanreotide reduces gastrointestinal motility and may decrease cyclosporine absorption, necessitating monitoring of cyclosporine trough concentrations and dose adjustment [17].

Bromocriptine: Somatostatin analogs may increase the bioavailability of bromocriptine through decreased gastrointestinal metabolism. Concurrent use in acromegaly or prolactinoma treatment requires monitoring for bromocriptine adverse events [17].

CYP450 substrates with narrow therapeutic index: Lanreotide suppresses growth hormone, which regulates hepatic expression of certain CYP450 enzymes. Normalization of growth hormone in acromegaly patients may alter the clearance of CYP450 substrates including warfarin, terfenadine, and carbamazepine. Monitoring of drug levels and clinical effect is appropriate when initiating lanreotide in patients on narrow-therapeutic-index drugs [17].

QT-prolonging agents: Sinus bradycardia is reported in 3 to 8 percent of lanreotide-treated patients. Concurrent use with other bradycardia-inducing agents (beta-blockers, calcium channel blockers, digitalis glycosides) or QT-prolonging agents warrants electrocardiographic monitoring [10].

Other somatostatin analogs: Concurrent use with octreotide, pasireotide, or other somatostatin analogs is pharmacologically redundant for the SSTR2 agonist effect and may produce additive adverse events (gallbladder stasis, gastrointestinal effects, dysglycemia). Sequential use (switching from octreotide to lanreotide or to pasireotide) is clinically established; concurrent use is not standard.

Peptide receptor radionuclide therapy (PRRT): Lanreotide and octreotide may compete with radiolabeled somatostatin analogs (¹⁷⁷Lu-DOTATATE, ⁹⁰Y-DOTATOC) for SSTR2 binding. Protocols for PRRT typically require washout of long-acting somatostatin analogs (4 to 6 weeks for Autogel/LAR formulations) before radiopeptide administration to avoid receptor saturation. Some protocols permit concurrent cold somatostatin analog therapy at reduced doses; this remains an area of active investigation [32].

mTOR inhibitors: The combination of lanreotide with everolimus has been studied in neuroendocrine tumors on the basis of preclinical synergy data. The RADIANT-3 trial demonstrated everolimus benefit in pancreatic NETs; post hoc analyses of patients receiving concurrent somatostatin analogs (including lanreotide) suggested additive or synergistic benefit. Preclinical data from Vitale et al. (2020) support the combination rationale [26, 33].

11. Adverse Events and Safety Signal

11.1 Common adverse events

The principal adverse events at registered doses (60 to 120 mg every 28 days by deep subcutaneous injection) in pooled clinical trial data are:

- Diarrhea (26 to 65 percent, depending on indication and study; reflects suppression of pancreatic exocrine secretion and alteration of gastrointestinal motility)
- Abdominal pain (7 to 34 percent)
- Nausea (5 to 11 percent)
- Vomiting (5 to 19 percent)
- Flatulence (3 to 14 percent)
- Injection site reactions (pain, induration, nodule, pruritus; 5 to 22 percent)
- Cholelithiasis and gallbladder sludge (14 to 20 percent; reflects SST2-mediated suppression of gallbladder contractility)
- Headache (5 to 7 percent)
- Dysglycemia (hyperglycemia 5 to 14 percent; hypoglycemia 2 to 7 percent; diabetes mellitus in 5 to 7 percent)
- Sinus bradycardia (3 to 8 percent)
- Weight loss (3 to 5 percent) [10]

The gastrointestinal adverse events are the most common and are generally mild to moderate in severity; they tend to diminish with continued treatment. The diarrhea may paradoxically alternate with constipation or steatorrhea, reflecting the complex effects of somatostatin analog action on gastrointestinal secretion and motility.

11.2 Gallbladder and biliary adverse events

Cholelithiasis is the most clinically significant non-gastrointestinal adverse event. In acromegaly studies, cholelithiasis and gallbladder sludge were reported in approximately 20 percent of patients; in GEP-NET studies, the rate was approximately

14 percent [10]. The risk increases with dose and duration of treatment. Postmarketing reports have documented progression to cholecystitis, cholangitis, and pancreatitis requiring cholecystectomy. Ultrasonographic monitoring of the gallbladder before initiation and periodically during treatment is recommended in some guidelines.

11.3 Cardiac adverse events

Sinus bradycardia is reported in 3 to 8 percent of patients. In pooled cardiac safety studies in acromegaly, sinus bradycardia occurred in 5.5 percent and clinically significant bradycardia (heart rate less than 50 beats per minute) in 2.8 percent [10]. Hypertension was reported in 5.5 percent. QT prolongation has not been specifically attributed to lanreotide in the clinical trial database but is a theoretical concern given the bradycardia effect and the QT-prolongation signal observed with the broader somatostatin analog class.

11.4 Metabolic adverse events

Dysglycemia is a pharmacologically predictable consequence of suppression of both insulin and glucagon secretion. In acromegaly patients, adverse reactions of dysglycemia (hypoglycemia, hyperglycemia, new-onset diabetes) were reported by 14 percent and considered drug-related in 7 percent [10]. In GEP-NET patients, hyperglycemia was reported in 14 percent. The metabolic risk is lower than for pasireotide (which has a substantially higher hyperglycemia rate of 28 to 33 percent), reflecting the narrower SSTR5 engagement of lanreotide compared to pasireotide [22, 34].

11.5 Hepatic effects

Transient elevations of hepatic transaminases have been reported rarely. The LiverTox database classifies lanreotide as having a low likelihood of clinically apparent liver injury [35].

11.6 Pregnancy and lactation

Animal studies have shown embryofetal toxicity at doses exceeding clinical exposures. Human pregnancy data are absent. Lanreotide is generally not recommended in pregnancy or lactation [10].

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five somatostatin receptor ligands and related agents against lanreotide, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected as the principal agents that compete with or complement lanreotide in the clinical management of acromegaly and neuroendocrine tumors.

12.1 Octreotide (Sandostatin, Sandostatin LAR)

Mechanism: Synthetic cyclic octapeptide somatostatin analog with preferential SSTR2 and SSTR5 agonism. Binding affinity profile is similar to lanreotide: SSTR2 Ki approximately 0.56 nM, SSTR5 Ki approximately 7 nM [18, 19].

Development trajectory: Developed by Sandoz (now Novartis), octreotide was the first somatostatin analog to achieve clinical registration, approved by the FDA in 1988 for acromegaly and carcinoid syndrome as the immediate-release subcutaneous injection (Sandostatin). The long-acting release formulation (Sandostatin LAR, microsphere depot for intramuscular injection every 28 days) was approved in 1998. Octreotide LAR is the most widely used somatostatin analog globally [18, 19].

Novelty: Low. Octreotide is the reference compound for the first-generation somatostatin analog class. The mechanism is identical to lanreotide at the receptor level.

Effect size: In acromegaly, octreotide LAR normalizes GH in approximately 55 to 65 percent and IGF-1 in approximately 45 to 55 percent of treatment-naïve patients, broadly comparable to lanreotide Autogel [8]. In neuroendocrine tumors, the PROMID trial demonstrated a hazard ratio for time to progression of 0.34 (95 percent CI 0.20 to 0.59) with octreotide LAR versus placebo in midgut neuroendocrine tumors, numerically favorable to the CLARINET lanreotide result but in a more selected population [29].

Promising potential: Stable. Octreotide remains the market leader but faces generic competition and does not have new indications in development.

Side-effect profile: Similar to lanreotide. Gastrointestinal effects, cholelithiasis, and injection site reactions are the principal adverse events. The LAR formulation requires intramuscular injection by a healthcare provider (not self-injectable) and has occasional injection site complications (granuloma, abscess).

Overall validation: Very high. The largest clinical evidence base, the longest postmarketing experience, and the broadest global access of any somatostatin analog.

Comparison to lanreotide: The two compounds are therapeutically equivalent at the receptor level. Lanreotide's principal advantages are the Autogel self-injectable subcutaneous formulation (versus the LAR intramuscular healthcare-provider-administered injection), the CLARINET trial evidence for antiproliferative effect in a broader NET population than PROMID, and the self-assembling nanotube technology. Octreotide's principal advantages are a longer regulatory and clinical track record, broader global availability, and extensive generic competition that reduces cost.

12.2 Pasireotide (Signifor, Signifor LAR)

Mechanism: Second-generation multireceptor somatostatin analog with binding affinity at all five SSTR subtypes. Distinguished from octreotide and lanreotide by approximately 40-fold higher affinity at SSTR5, 30-fold higher affinity at SSTR1, and 5-fold higher affinity at SSTR3, with similar affinity at SSTR2 [22, 34].

Development trajectory: Developed by Novartis. Approved by the FDA in 2012 for Cushing's disease (the only somatostatin analog approved for this indication, targeting SSTR5 on corticotroph adenomas) and in 2014 for acromegaly in patients inadequately controlled by surgery and first-generation somatostatin analogs.

Novelty: High. The multireceptor binding profile, including high SSTR5 affinity, is mechanistically distinct from first-generation analogs and enables clinical activity in Cushing's disease and in acromegaly resistant to octreotide and lanreotide.

Effect size: In the PAOLA trial (Gadelha et al. 2014), pasireotide LAR 40 mg and 60 mg monthly achieved biochemical control (GH less than 2.5 micrograms per liter and normal IGF-1) in 15 and 20 percent of patients inadequately controlled on oc-

treotide or lanreotide, compared to 0 percent in the active control group continuing first-generation analog therapy [34]. This establishes pasireotide as the rescue agent for first-generation analog failure, but with a modest absolute response rate.

Promising potential: Moderate. Established second-line role in acromegaly and first-line role in Cushing's disease. No ongoing expansion of indications in NETs.

Side-effect profile: Substantially higher rates of hyperglycemia and new-onset diabetes (28 to 33 percent) compared to octreotide and lanreotide (7 to 14 percent), reflecting the broader SSTR5-mediated insulin suppression [34]. This is the principal safety liability and limits use to patients with adequate glycemic reserve or willingness to initiate diabetic pharmacotherapy.

Overall validation: Moderate to high. Well validated for Cushing's disease and for second-line acromegaly treatment. Not validated as an antiproliferative agent in NETs.

Comparison to lanreotide: Pasireotide is complementary rather than competitive with lanreotide. Lanreotide is the first-line agent with a broader safety profile and a three-indication portfolio; pasireotide is the second-line agent for first-generation analog failure, with a narrower indication set and higher metabolic toxicity.

12.3 Somatoprim (DG3173)

Mechanism: Novel somatostatin analog with preferential SSTR2, SSTR4, and SSTR5 agonism and low affinity at SSTR1 and SSTR3. The SSTR4 engagement is unique among clinically studied somatostatin analogs and may contribute to analgesic and anti-inflammatory effects distinct from the SSTR2/SSTR5-dominated activity of the first-generation compounds [36].

Development trajectory: Developed by DeveloGen (later Evotec). Phase 1 and Phase 2a studies in acromegaly have been completed, demonstrating GH suppression with potentially reduced hyperglycemia relative to first-generation analogs [36]. Development status is uncertain; the compound is not registered and is not in advanced clinical trials.

Novelty: High. The SSTR4 component is unique in the clinical somatostatin analog space and may offer differentiated anti-nociceptive and anti-inflammatory properties.

Effect size: Phase 2a data in acromegaly demonstrated GH suppression comparable to short-acting octreotide. No antiproliferative data in NETs.

Promising potential: Low to moderate. The compound is in early clinical development with uncertain trajectory.

Side-effect profile: Limited data. Phase 1 and 2a studies reported favorable glycemic tolerability compared to octreotide, potentially attributable to the altered receptor selectivity profile [36].

Overall validation: Low. Early-phase clinical data only.

Comparison to lanreotide: Somatoprim is a research-stage compound without registered indications, clinical evidence base, or established safety profile. Lanreotide has the advantage of three registered indications, extensive clinical validation, and a mature safety database. Somatoprim's unique SSTR4 engagement is of scientific interest but has not been translated to demonstrated clinical benefit.

12.4 ¹⁷⁷Lu-DOTATATE (Lutathera)

Mechanism: Radiolabeled somatostatin analog for peptide receptor radionuclide therapy (PRRT). ¹⁷⁷Lu-DOTATATE consists of the SSTR2-binding chelator-peptide DOTA-Tyr3-octreotate labeled with the beta-emitting radionuclide lutetium-177, which delivers targeted radiation to SSTR2-expressing tumor cells [32, 37].

Development trajectory: Developed by Advanced Accelerator Applications (now Novartis). Approved by the FDA in January 2018 for the treatment of SSTR-positive gastroenteropancreatic neuroendocrine tumors in adults, based on the NETTER-1 trial (Strosberg et al. 2017) [37].

Novelty: High. PRRT is a fundamentally different modality from cold somatostatin analog therapy, using the same receptor-targeting principle for therapeutic radiation delivery rather than hormonal suppression.

Effect size: In the NETTER-1 trial, ¹⁷⁷Lu-DOTATATE plus octreotide LAR 30 mg versus octreotide LAR 60 mg (high dose) produced a hazard ratio for PFS of 0.21 (95 percent CI 0.13 to 0.33; P less than 0.001), with estimated PFS at 20 months of 65.2 percent versus 10.8 percent [37]. This is the largest treatment effect demonstrated in the neuroendocrine tumor space and substantially exceeds the effect size of cold somatostatin analog monotherapy.

Promising potential: High. Active clinical development in expanded indications (NETTER-2 in grade 2-3 GEP-NETs, combination studies). PRRT is becoming a standard treatment modality in advanced NETs.

Side-effect profile: The principal adverse events are bone marrow suppression (lymphopenia, thrombocytopenia, leukopenia), nausea and vomiting during infusion, and renal toxicity with cumulative doses. Myelodysplastic syndrome and acute leukemia have been reported as rare delayed adverse events (1 to 2 percent) [37].

Overall validation: High. Phase 3 evidence with large effect size, FDA approval, and growing real-world experience.

Comparison to lanreotide: ¹⁷⁷Lu-DOTATATE and lanreotide are complementary rather than competitive. Lanreotide is first-line antiproliferative therapy for stable or slowly progressive SSTR-positive NETs; ¹⁷⁷Lu-DOTATATE is used for progressive disease after failure of or in combination with cold somatostatin analogs. The treatment sequence in many patients involves initial lanreotide followed by ¹⁷⁷Lu-DOTATATE at progression. Washout of long-acting lanreotide is required before PRRT to avoid receptor competition.

12.5 Surufatinib (Sulanda)

Mechanism: Oral multi-kinase inhibitor targeting VEGFR1/2/3, FGFR1, and CSF-1R. The anti-angiogenic and immunomodulatory mechanisms are mechanistically distinct from somatostatin receptor agonism [38].

Development trajectory: Developed by Hutchison MediPharma (now HUTCHMED). Approved in China in 2020 and 2021 for non-pancreatic and pancreatic neuroendocrine tumors, respectively. Phase 3 trials in the United States (SANET-ep and SANET-p) demonstrated PFS benefit versus placebo in both pancreatic and extra-pancreatic NETs [38].

Novelty: High. Tyrosine kinase inhibition is a fundamentally different mechanism from somatostatin receptor agonism.

Effect size: In Phase 3 studies, surufatinib versus placebo produced hazard ratios for PFS of approximately 0.33 to 0.49, comparable to or numerically better than the CLARINET lanreotide result [38].

Promising potential: Moderate to high. Approved in China; under regulatory review or in advanced trials for other markets. Combination with somatostatin analogs is under investigation.

Side-effect profile: The principal adverse events include hypertension (45 to 60 percent), proteinuria (30 to 40 percent), hepatic enzyme elevation, diarrhea, and hand-foot syndrome, reflecting the anti-angiogenic mechanism. The side-effect profile is substantially different from and generally more burdensome than that of somatostatin analogs [38].

Overall validation: Moderate. Phase 3 evidence in China; regulatory status outside China is evolving.

Comparison to lanreotide: Surufatinib is a fundamentally different therapeutic modality that may complement lanreotide in the treatment of neuroendocrine tumors. Lanreotide has the advantages of a well-established global regulatory portfolio, a favorable side-effect profile, established use as first-line therapy, and decades of clinical experience. Surufatinib may offer benefit in patients progressing on somatostatin analogs, particularly in combination regimens.

12.6 Comparator summary

The five comparators occupy distinct positions in the somatostatin-receptor and neuroendocrine-tumor therapeutic landscape. **Octreotide** is the direct therapeutic equivalent of lanreotide at the receptor level, differing principally in formulation technology (microsphere LAR versus self-assembling Autogel) and in self-injection capability. **Pasireotide** is the second-generation, multireceptor analog for first-generation failure, with higher efficacy in a subset of acromegaly patients but substantially higher metabolic toxicity. **Somatoprim** is a novel early-phase compound with a unique SSTR4 component but no clinical validation. **¹⁷⁷Lu-DOTATATE** is the most effective antiproliferative agent in the NET space, operating through targeted radiation rather than hormonal suppression, and is used sequentially after lanreotide in the standard treatment algorithm. **Surufatinib** represents the tyrosine kinase inhibitor modality with Phase 3 evidence in NETs but a substantially different and more burdensome side-effect profile.

Lanreotide occupies a central position in this therapeutic landscape: it is one of two established first-generation somatostatin analogs with a three-indication regulatory portfolio, the only somatostatin analog with a self-assembling nanotube de-

pot formulation enabling self-injection, and the compound on which the CLARINET trial established the standard of evidence for antiproliferative somatostatin analog therapy in gastroenteropancreatic neuroendocrine tumors. Its principal limitation relative to the newer modalities (PRRT, TKIs) is the modest absolute effect size of hormonal antiproliferative therapy, which is nonetheless sufficient for first-line management of stable or slowly progressive disease and which is achieved with a substantially more favorable toxicity profile than the alternative modalities.

13. References

1. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. *Nat Rev Drug Discov.* 2003;2(12):999-1017.
2. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. *N Engl J Med.* 1996;334(4):246-254.
3. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. *J Pharm Pharmacol.* 2004;56(4):471-476.
4. Adelman DT, Burgess A, Davies RR. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. *Clin Pharmacokinet.* 2009;48(2):113-122.
5. Drugs.com. Somatuline Depot (lanreotide acetate) FDA Approval History. Accessed 2026.
6. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. *N Engl J Med.* 2014;371(3):224-233.
7. Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA; ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. *Endocr Pract.* 2016;22(9):1068-1080.
8. Caron PJ, Bevan JS, Petersenn S, et al. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. *J Clin Endocrinol Metab.* 2014;99(4):1282-1290.
9. Lucas T, Astorga R; Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. *Clin Endocrinol (Oxf).* 2006;65(3):320-326.
10. Ipsen Biopharmaceuticals, Inc. Somatuline Depot (lanreotide) injection, for subcutaneous use: full prescribing information. U.S. Food and Drug Administration. 2024.

11. Coy DH, Murphy WA. Somatostatin analogs: current status. In: Conn PM, ed. Somatostatin and Its Receptors. Methods in Neurosciences. Vol 24. Academic Press; 1995:187-202.
12. Chandrashekar S, Soumyanath A. Solid-phase synthesis and characterization of somatostatin analogs. Peptides. 2000;21(9):1357-1365.
13. Valery C, Paternostre M, Robert B, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci U S A. 2003;100(18):10258-10262.
14. Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.
15. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin mediated through somatostatin receptors. Trends Endocrinol Metab. 2008;19(3):75-82.
16. Colao A, Ferone D, Marzullo P, et al. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001;24(4):209-216.
17. Ipsen Biopharmaceuticals, Inc. Somatuline Depot (lanreotide) drug interactions section, full prescribing information. FDA label. 2024.
18. Bauer W, Briner U, Doeppfner W, et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31(11):1133-1140.
19. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313(25):1576-1580.
20. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Otal P. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64(2):209-214.
21. Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71(2):502-513.

22. Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. *Mol Cell Endocrinol*. 2008;286(1-2):69-74.
23. Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. *Front Neuroendocrinol*. 2013;34(3):228-252.
24. Troconiz IF, Cendros JM, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel/Depot in the treatment of neuroendocrine tumors: pooled analysis of four clinical trials. *Clin Pharmacokinet*. 2015;54(12):1241-1250.
25. Savelli G, Lunardi G, Lunghi A, et al. Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells. *Front Pharmacol*. 2024;15:1308686.
26. Vitale G, Dicitore A, Pepe D, et al. Lanreotide induces cytokine modulation in intestinal neuroendocrine tumors and overcomes resistance to everolimus. *Front Oncol*. 2020;10:1047.
27. Caron PJ, Bevan JS, Petersenn S, et al. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. *Pituitary*. 2016;19(2):149-157.
28. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. *Eur J Endocrinol*. 2009;161(2):331-338.
29. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol*. 2009;27(28):4656-4663.
30. Wolin EM, Jarzab B, Eriksson B, et al. Patient-reported symptom control of diarrhea and flushing in patients with neuroendocrine tumors treated with lanreotide depot/autogel: results from a randomized, placebo-controlled, double-blind and 32-week open-label study. *Oncologist*. 2018;23(1):16-24.
31. Meijer E, Visser FW, van Aerts RMM, et al. Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial. *JAMA*. 2018;320(19):2010-2019.

32. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617-4624.
33. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
34. Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875-884.
35. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. Lanreotide. Updated 2020.
36. Plockinger U, Albrecht S, Gerstenberger J, et al. Somatoprim (DG3173): a unique somatostatin receptor analog with preferential SSTR2, SSTR4 and SSTR5 binding. Abstracts of the 14th International Congress of Endocrinology. Horm Res. 2010;73(Suppl 3):S89.
37. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135.
38. Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1500-1512.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Lanreotide is approved by the United States Food and Drug Administration for the treatment of acromegaly, gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. The compound is registered in more than 60 jurisdictions worldwide. Investigators should consult their local regulatory authority before any human research application.